EDQM Releases Document on Recombinant Viral Vectored Vaccines for COVID-19
The document provides analytical strategy options for the control of recombinant viral vectored vaccines to support COVID-19 vaccine developers.
The European Directorate for the Quality of Medicines and HealthCare (EDQM) announced on Nov. 3, 2020 the release of a document that discusses the control of viral vectored vaccines. The document was created in collaboration with the European Pharmacopoeia Group of Experts on vaccines for human use to support COVID-19 vaccine developers.
The document, titled “Recombinant Viral Vectored Vaccines for Human Use”, provides analytical strategy options for the control of recombinant viral vectored vaccines and includes recommendations on tests that can be used as an aid “in building appropriate analytical strategies,” EDQM stated in a press release. Topics covered in the document include substrate for recombinant viral vector propagation, recombinant viral vector seed lot propagation and harvest, purified harvest, final bulk, and final lot.
Source: EDQM
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
AES Clean Technology Launches Next-Generation OSM Utility Solution for Cleanrooms at INTERPHEX 2025
April 2nd 2025Officially launched at INTERPHEX 2025, the Omni ASCENT is a next-generation off-site manufactured vertical utility solution that offers optimized cleanroom flexibility and efficiency.
